AI주식인사이트AI Stock Insight
C

현대바이오랜드

052260KOSDAQ기타 화학제품 제조업

50.5 / 100

Reference Date: 2026-04-13

Financial Score21.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai BioLand operates in various sectors including cosmetics, health supplements, pharmaceutical ingredients, medical devices, and brand distribution, leveraging natural bio-materials. The company focuses on developing high-value products such as hyaluronic acid and plant-based collagen, while expanding global partnerships. It emphasizes R&D to meet environmental regulations and consumer trends, and is actively growing its market presence through innovative technologies and strategic collaborations.

Number of Employees

342people

Average Salary

66.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
521.25Industry Average 18.380.0Point

28.4x industry avg (risky)

PBR
0.92Industry Average 1.375.5Point

Lower than industry avg (good)

ROE
0.18Industry Average 4.551.0Point

Well below industry avg

Debt Ratio
1.84Industry Average 8.138.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲54.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 3.5% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 4,170Won52-week high 5,34052-week low 3,990
1-month return3.0Point

1m 0.36% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0
  • Positive배당락2026-04-01
  • Neutral정기주주총회결과2026-03-20
  • Neutral기업가치제고계획(자율공시)2026-03-20